At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Closed 03-18 16:00:00 EDT
39.65
+0.98
+2.53%
盘后39.65
+0.000.00%
16:05 EDT
| High40.98 | Low38.75 | Vol516.38K |
| Open39.50 | D1 Closing38.67 | Amplitude5.78% |
| Mkt Cap2.51B | Tradable Cap1.12B | Total Shares63.28M |
| T/O20.65M | T/O Rate1.83% | Tradable Shares28.14M |
| P/B5.62 | ROE-25.08% | EPS-1.89 |
| 52wk High58.26 | 52wk Low36.52 | P/E-20.96 |
| Dividend0.00 | Div.Yield0.00 | ROA-17.81% |
MoonLake Immunotherap Initiated at Outperform by RBC Capital
Dow Jones · 03-18 15:40
RBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)
TIPRANKS · 03-18 10:35
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target
MT Newswires Live · 03-18 10:27
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases
TIPRANKS · 03-12
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow Jones · 02-27
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals
TIPRANKS · 02-27
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential
TIPRANKS · 02-26
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position
TIPRANKS · 02-26
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments
TIPRANKS · 02-26
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements
TIPRANKS · 02-26
MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02-26
MoonLake Immunotherapeutics Q4 Loss Widens
MT Newswires Live · 02-26
MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026
Benzinga · 02-26
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss
MT Newswires Live · 02-26
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c)
TIPRANKS · 02-26
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
THOMSON REUTERS · 02-26
MoonLake Immunotherapeutics FY EPS USD -1.89
THOMSON REUTERS · 02-26
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire · 02-26
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?
Insider Monkey · 02-25
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts
Insider Monkey · 02-23
Introduction
Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
2020-10-20
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
10.00
Invest in Global Markets with Tiger Brokers!Open App